期刊文献+

中西医结合治疗冠心病伴血脂异常的疗效和安全性分析 被引量:11

Assessment of the effects and clinical safety in the treatment of coronary heart disease with combination of Chinese tradiational and western medicine
下载PDF
导出
摘要 目的探讨中西医结合治疗冠心病(CHD)伴血脂异常的疗效和安全性。方法回顾性分析我院2012年3月~2013年3月收治的冠心病患者68例,根据治疗方法分成中药组36例和对照组32例。两组均给予一般对症治疗,中药组加用复元活血汤加减治疗,对照组加用通心络胶囊,比较治疗后两组总体临床疗效及安全性,及血清甘油三酯(TG)、血清总胆固醇(TC)、低密度脂蛋白(LDL—C)、高密度脂蛋白(HDL—C)变化,并比较其不良反应发生情况。结果中药组与对照组临床总有效率分别为88.9%(32/36),71.9%(23/32),TG、TC、LDL—C水平比较,差异均有统计学意义(均P〈0.05)。两组仅出现轻微胃肠道不良反应。结论中西医联合治疗CHD可以提高临床有效率,降低血脂水平,且安全性较好。 Objective To explore the effects and clinical safety in the treatment of coronary heart disease with combination of Chinese tradiational and western medicine. Methods 68 CHD cases from March 2012 to March 2013 were analyzed retrospectively and divided into traditional Chinese medicine group(36 cases)and control group(32 cases) according to the treatment method.All the cases were given general symptomatic treatment. On this basis, traditional Chinese medicine group was given Fuyuan Huoxue tang and the control group was given Tongxinluo capsule. The clinical curative effect,serum triglyceride(TG), Serum total cholesterol (TC), low density lipoprotein (LDL- C), high density lipoprotein (HDL-C) and safety were compared after treatment. Results The clinical total effective rate of treatment group and control group were88.9%(32/36) and71.9%(23/32). The level of TG, TC and LDL-C comparison (P 〈 0.05) in two groups after treatment. Gastrointestinal adverse reaction in two groups was slight. Conclusion Combination of Chinese tradiational and western medicine in the treatment of CHD have curative effect,can reduce blood lipid levels effectively and have better security.
作者 苏士印
出处 《中国医药科学》 2013年第16期82-83,共2页 China Medicine And Pharmacy
关键词 冠心病 血脂 复元活血汤 通心络胶囊 安全性 Coronary heart disease Blood fat Fuyuan Huoxue tang Tongxinluo capsule Safety
  • 相关文献

参考文献7

二级参考文献33

  • 1全国血压抽样调查协作组.中国人群高血压患病率及其变化趋势[J].高血压杂志,1995,3(A01):7-13. 被引量:508
  • 2白丽杰,王艳.洛伐他汀治疗冠心病高脂血症疗效观察[J].中国误诊学杂志,2006,6(16):3091-3092. 被引量:3
  • 3韩莉莉,路中卫,孟宪亮,于杰,郭伟星.浅谈黄芪对冠心病的治疗作用[J].光明中医,2007,22(2):53-55. 被引量:8
  • 4陈国伟,宗锷,主编.现代心脏内科学[M].长沙:湖南科技出版社,2005:936-928.
  • 5张琴,薛明华,张迅英,鞠红,朱蕾,孟海燕.阿托伐他汀对冠心病心力衰竭患者预后的影响[J].临床荟萃,2007,22(17):1261-1262. 被引量:3
  • 6Young YX,Jabbour S,Golderg R,et al.Usefulness of starlin drougs in protecting against areal fidrilation in patients with coronary artery disease[J].Am J Cardiol,2003,92:1379-1383.
  • 7国际心脏学会与世界卫生组织命名标准化联合专题组.缺血性心脏病的命名及诊断标准.中华内科杂志,1981,:254-254.
  • 8European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J, 2011,32 : 1769-1818.
  • 9中华人民共和国卫生部.中药新药临床研究指导原则[J]第1辑[Z].,1993.308.
  • 10陈灏珠.实用内科学[M].北京:人民卫生出版社,2001.953.

共引文献3114

同被引文献68

引证文献11

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部